ProtoKinetix, Incorporated (PKTX)
USD 0.01
(-16.79%)
USD 0.01
(-16.79%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 44.69 Thousand USD | 7.62% |
| 2022 | 41.53 Thousand USD | -55.47% |
| 2021 | 93.26 Thousand USD | 107.45% |
| 2020 | 44.96 Thousand USD | 76.18% |
| 2019 | 25.52 Thousand USD | -67.65% |
| 2018 | 78.88 Thousand USD | -45.43% |
| 2017 | 144.56 Thousand USD | 219.16% |
| 2016 | 45.29 Thousand USD | -0.2% |
| 2015 | 45.38 Thousand USD | -89.55% |
| 2014 | 434.14 Thousand USD | -32.46% |
| 2013 | 642.79 Thousand USD | 24.6% |
| 2012 | 515.89 Thousand USD | 5.26% |
| 2011 | 490.12 Thousand USD | -8.83% |
| 2010 | 537.59 Thousand USD | 4.93% |
| 2009 | 512.32 Thousand USD | 29.75% |
| 2008 | 394.84 Thousand USD | -3.42% |
| 2007 | 408.82 Thousand USD | -1.42% |
| 2006 | 414.7 Thousand USD | -16.66% |
| 2005 | 497.59 Thousand USD | -33.9% |
| 2004 | 752.83 Thousand USD | 357.89% |
| 2003 | 164.41 Thousand USD | 1253.87% |
| 2002 | 12.14 Thousand USD | 5972.0% |
| 2001 | 200.00 USD | 0.0% |
| 2000 | 200.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 67.56 Thousand USD | 51.17% |
| 2024 Q2 | 58.76 Thousand USD | -13.03% |
| 2023 Q1 | 53 Thousand USD | 27.62% |
| 2023 Q2 | 13.25 Thousand USD | -74.99% |
| 2023 FY | 44.69 Thousand USD | 7.62% |
| 2023 Q3 | 12.56 Thousand USD | -5.23% |
| 2023 Q4 | 44.69 Thousand USD | 255.8% |
| 2022 Q2 | 36.78 Thousand USD | 425.43% |
| 2022 FY | 41.53 Thousand USD | -55.47% |
| 2022 Q1 | 7000.00 USD | -92.49% |
| 2022 Q3 | 105.03 Thousand USD | 185.57% |
| 2022 Q4 | 41.53 Thousand USD | -60.46% |
| 2021 FY | 93.26 Thousand USD | 107.45% |
| 2021 Q3 | 7000.00 USD | 40.0% |
| 2021 Q4 | 93.26 Thousand USD | 1232.4% |
| 2021 Q1 | 5000.00 USD | -88.88% |
| 2021 Q2 | 5000.00 USD | 0.0% |
| 2020 FY | 44.96 Thousand USD | 76.18% |
| 2020 Q3 | 5000.00 USD | -83.33% |
| 2020 Q4 | 44.96 Thousand USD | 799.2% |
| 2020 Q2 | 30 Thousand USD | 3.92% |
| 2020 Q1 | 28.86 Thousand USD | 13.12% |
| 2019 Q4 | 25.52 Thousand USD | 370.76% |
| 2019 Q3 | 5421.00 USD | 0.02% |
| 2019 Q1 | 70.65 Thousand USD | -10.44% |
| 2019 FY | 25.52 Thousand USD | -67.65% |
| 2019 Q2 | 5420.00 USD | -92.33% |
| 2018 Q2 | 5420.00 USD | -29.89% |
| 2018 Q1 | 7731.00 USD | -94.65% |
| 2018 FY | 78.88 Thousand USD | -45.43% |
| 2018 Q4 | 78.88 Thousand USD | 1471.41% |
| 2018 Q3 | 5020.00 USD | -7.38% |
| 2017 Q4 | 144.56 Thousand USD | 629.45% |
| 2017 FY | 144.56 Thousand USD | 219.16% |
| 2017 Q3 | 19.81 Thousand USD | 269.12% |
| 2017 Q2 | 5369.00 USD | -88.41% |
| 2017 Q1 | 46.31 Thousand USD | 2.25% |
| 2016 Q3 | 40.38 Thousand USD | -63.98% |
| 2016 Q1 | 89.52 Thousand USD | 97.25% |
| 2016 FY | 45.29 Thousand USD | -0.2% |
| 2016 Q4 | 45.29 Thousand USD | 12.16% |
| 2016 Q2 | 112.11 Thousand USD | 25.22% |
| 2015 Q4 | 45.38 Thousand USD | -42.68% |
| 2015 Q3 | 79.17 Thousand USD | -62.73% |
| 2015 Q2 | 212.46 Thousand USD | -23.12% |
| 2015 Q1 | 276.36 Thousand USD | -36.34% |
| 2015 FY | 45.38 Thousand USD | -89.55% |
| 2014 Q1 | 593.62 Thousand USD | -7.65% |
| 2014 FY | 434.14 Thousand USD | -32.46% |
| 2014 Q4 | 434.14 Thousand USD | -31.68% |
| 2014 Q3 | 635.46 Thousand USD | 3.07% |
| 2014 Q2 | 616.54 Thousand USD | 3.86% |
| 2013 Q3 | 570.32 Thousand USD | 2.15% |
| 2013 Q2 | 558.29 Thousand USD | 0.72% |
| 2013 Q1 | 554.29 Thousand USD | 7.44% |
| 2013 FY | 642.79 Thousand USD | 24.6% |
| 2013 Q4 | 642.79 Thousand USD | 12.71% |
| 2012 Q2 | 460.87 Thousand USD | 3.2% |
| 2012 Q3 | 468.92 Thousand USD | 1.75% |
| 2012 FY | 515.89 Thousand USD | 5.26% |
| 2012 Q4 | 515.89 Thousand USD | 10.02% |
| 2012 Q1 | 446.56 Thousand USD | -8.89% |
| 2011 FY | 490.12 Thousand USD | -8.83% |
| 2011 Q4 | 490.12 Thousand USD | 3.72% |
| 2011 Q3 | 472.54 Thousand USD | 19.36% |
| 2011 Q2 | 395.91 Thousand USD | 77.22% |
| 2011 Q1 | 223.4 Thousand USD | -58.44% |
| 2010 Q1 | 505.75 Thousand USD | -1.28% |
| 2010 FY | 537.59 Thousand USD | 4.93% |
| 2010 Q4 | 537.59 Thousand USD | 14.14% |
| 2010 Q3 | 470.98 Thousand USD | -8.44% |
| 2010 Q2 | 514.4 Thousand USD | 1.71% |
| 2009 Q4 | 512.32 Thousand USD | 1.96% |
| 2009 Q2 | 542.7 Thousand USD | 20.0% |
| 2009 Q1 | 452.24 Thousand USD | 14.54% |
| 2009 FY | 512.32 Thousand USD | 29.75% |
| 2009 Q3 | 502.46 Thousand USD | -7.41% |
| 2008 FY | 394.84 Thousand USD | -3.42% |
| 2008 Q4 | 394.84 Thousand USD | 12.67% |
| 2008 Q3 | 350.44 Thousand USD | 16.65% |
| 2008 Q2 | 300.42 Thousand USD | -25.11% |
| 2008 Q1 | 401.17 Thousand USD | -1.87% |
| 2007 FY | 408.82 Thousand USD | -1.42% |
| 2007 Q3 | 545.28 Thousand USD | 22.79% |
| 2007 Q4 | 408.82 Thousand USD | -25.03% |
| 2007 Q2 | 444.08 Thousand USD | 2.45% |
| 2007 Q1 | 433.45 Thousand USD | 4.52% |
| 2006 FY | 414.7 Thousand USD | -16.66% |
| 2006 Q2 | 402.34 Thousand USD | -31.97% |
| 2006 Q3 | 328.52 Thousand USD | -18.35% |
| 2006 Q4 | 414.7 Thousand USD | 26.23% |
| 2006 Q1 | 591.38 Thousand USD | 18.85% |
| 2005 Q3 | 586.45 Thousand USD | -0.28% |
| 2005 FY | 497.59 Thousand USD | -33.9% |
| 2005 Q4 | 497.59 Thousand USD | -15.15% |
| 2005 Q2 | 588.1 Thousand USD | -22.72% |
| 2005 Q1 | 761.04 Thousand USD | 1.09% |
| 2004 Q3 | 514.54 Thousand USD | 2.56% |
| 2004 Q1 | 490.94 Thousand USD | 198.6% |
| 2004 Q2 | 501.71 Thousand USD | 2.19% |
| 2004 Q4 | 752.83 Thousand USD | 46.31% |
| 2004 FY | 752.83 Thousand USD | 357.89% |
| 2003 Q4 | 164.41 Thousand USD | 57.15% |
| 2003 Q3 | 104.62 Thousand USD | 378.29% |
| 2003 FY | 164.41 Thousand USD | 1253.87% |
| 2003 Q2 | 21.87 Thousand USD | 0.0% |
| 2002 FY | 12.14 Thousand USD | 5972.0% |
| 2002 Q1 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 FY | 200.00 USD | 0.0% |
| 2000 FY | 200.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -62.928% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 99.528% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 99.938% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 94.474% |
| Rebus Holdings, Inc. | 5.24 Million USD | 99.147% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 99.924% |
| Qrons Inc. | 1.48 Million USD | 96.998% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | 96.355% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 99.94% |
| Skye Bioscience, Inc. | 14.07 Million USD | 99.682% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 99.916% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 99.534% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | 89.398% |
| SQZ Biotechnologies Company | 50.03 Million USD | 99.911% |
| Intellipharmaceutics International Inc. | 12 Million USD | 99.628% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 98.839% |
| Mesoblast Limited | 188.44 Million USD | 99.976% |
| Marizyme, Inc. | 26.67 Million USD | 99.832% |
| Genus plc | 485 Million USD | 99.991% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 99.235% |
| Pharming Group N.V. | 244.07 Million USD | 99.982% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 97.776% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 98.224% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 98.824% |
| ContraFect Corporation | 32.53 Million USD | 99.863% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 97.744% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 98.832% |
| IMV Inc. | 37.93 Million USD | 99.882% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 99.621% |
| MultiCell Technologies, Inc. | 1617.67 USD | -2662.986% |
| ONE Bio Corp. | 27.49 Million USD | 99.837% |
| Accustem Sciences Inc. | 1.07 Million USD | 95.859% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 99.942% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 97.887% |
| Q BioMed Inc. | 8.13 Million USD | 99.45% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.946% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 99.131% |
| Biomind Labs Inc. | 1.49 Million USD | 97.018% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.962% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 99.506% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 99.757% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 96.883% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | 68.545% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | 77.776% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 99.222% |
| GB Sciences, Inc. | 5.41 Million USD | 99.175% |
| Alpha Cognition Inc. | 7.16 Million USD | 99.376% |
| HST Global, Inc. | 593.59 Thousand USD | 92.47% |
| CSL Limited | 18.62 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 96.45% |
| Halberd Corporation | 728.71 Thousand USD | 93.866% |
| Enzolytics Inc. | 365.26 Million USD | 99.988% |
| Agentix Corp. | 2.51 Million USD | 98.22% |
| Resverlogix Corp. | 67.39 Million USD | 99.934% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 94.671% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.99% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 97.392% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 99.819% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 99.625% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 98.781% |
| AVAX Technologies, Inc. | 3.99 Million USD | 98.881% |
| Zenith Capital Corp. | 27.56 Thousand USD | -62.124% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.997% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | 81.272% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 98.803% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | 93.435% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 98.352% |
| Kadimastem Ltd | 3.5 Million USD | 98.725% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | 33.219% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 99.911% |
| BioStem Technologies, Inc. | 15.9 Million USD | 99.719% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | 90.382% |
| LadRx Corporation | 2.2 Million USD | 97.969% |
| Cell Source, Inc. | 15.8 Million USD | 99.717% |
| Regen BioPharma, Inc. | 5.45 Million USD | 99.181% |
| Regen BioPharma, Inc. | 5.45 Million USD | 99.181% |
| NovAccess Global Inc. | 7.86 Million USD | 99.431% |
| Affymax, Inc. | 8.87 Million USD | 99.496% |
| Itoco Inc. | 1.65 Million USD | 97.296% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 97.821% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 99.261% |
| Mobile Lads Corp. | 1.31 Million USD | 96.597% |
| CytoDyn Inc. | 127.89 Million USD | 99.965% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -6.931% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 97.147% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 99.595% |
| SYBLEU INC | 681.41 Thousand USD | 93.441% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 99.268% |
| International Stem Cell Corporation | 5.27 Million USD | 99.153% |
| Bioxytran, Inc. | 3.24 Million USD | 98.625% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | 92.858% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 99.032% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 99.891% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 99.799% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 97.793% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 99.184% |
| Neutra Corp. | 973.52 Thousand USD | 95.409% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 99.846% |
| PureTech Health plc | 125.58 Million USD | 99.964% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 98.81% |
| IXICO plc | 1.9 Million USD | 97.648% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 99.782% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.957% |
| CSL Limited | 18.62 Billion USD | 100.0% |
| Cellectis S.A. | 249.36 Million USD | 99.982% |